Equities

Relmada Therapeutics Inc

Relmada Therapeutics Inc

Actions
  • Price (USD)4.65
  • Today's Change0.06 / 1.31%
  • Shares traded1.44m
  • 1 Year change-73.96%
  • Beta-0.0132
Data delayed at least 15 minutes, as of Nov 30 2022 21:00 GMT.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Relmada Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), which is an N-methyl-D-aspartate (NMDA) receptor antagonist. The Company’s lead product candidate, esmethadone, is a new chemical entity (NCE) developed as a rapidly acting, oral agent for the treatment of depression, central nervous system (CNS) diseases and other potential indications. The Company’s lead program, REL-1017, is a novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission and is in development for both the adjunctive or monotherapy treatment of major depressive disorder (MDD).

  • Revenue in USD (TTM)0.00
  • Net income in USD-153.48m
  • Incorporated2012
  • Employees10.00
  • Location
    Relmada Therapeutics Inc2222 Ponce De Leon Blvd. 3Rd FloorCORAL GABLES 33134United StatesUSA
  • Phone+1 (646) 876-3459
  • Websitehttps://www.relmada.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Omeros Corporation-21.06m-197.97m134.24m213.00---------3.163.21-0.3363-0.7395-0.0725-----98,877.94-68.15-89.49-79.40-118.59--98.32---731.08---9.151.12-------10.64--17.06--
VBI Vaccines Inc870.00k-110.95m134.29m149.00--1.60--154.36-0.4298-0.42980.00340.32460.00442.7810.365,838.93-56.00-35.40-67.52-40.89-1,188.16-361.63-12,752.30-3,361.502.61-2.750.3662---40.532.86-50.88--27.81--
Cue Biopharma Inc9.35m-46.80m136.59m57.00--2.69--14.61-1.38-1.380.27631.430.1205--11.93164,006.50-60.32-56.36-72.23-65.49-----500.65-827.70----0.164--373.68--1.39--12.09--
VolitionRX Ltd200.91k-31.06m136.90m83.00--41.50--681.40-0.5721-0.57210.00370.05740.0075--16.032,420.60-117.61-91.10-201.60-110.87-----15,614.21-79,842.38---351.220.5973--570.44---31.75--18.59--
Larimar Therapeutics Inc0.00-35.06m137.16m31.00--1.16-----1.83-1.830.002.740.00----0.00-31.74-48.65-34.85-53.98------------0.00-------19.19---12.79--
Alaunos Therapeutics Inc2.91m-40.37m137.92m41.00--4.29--47.38-0.1878-0.18780.01350.14860.0322--1.3271,000.00-44.58-68.97-67.24-80.06-----1,386.64-5,538.19---12.330.4138-----43.421.53--43.24--
Taysha Gene Therapies Inc0.00-160.68m138.00m178.00--8.18-----4.12-4.120.000.27020.00----0.00-91.16---116.37-------------43.460.7725-------190.82------
Relmada Therapeutics Inc0.00-153.48m139.96m10.00--0.8007-----5.85-5.850.005.810.00----0.00-110.39---128.42-------------50.560.00-------111.50------
Celcuity Inc0.00-35.54m141.30m39.00--3.14-----2.38-2.380.002.910.00----0.00-45.24-44.12-48.14-45.72-----------23.190.2565-------212.48--14.90--
ORIC Pharmaceuticals Inc0.00-91.05m142.08m88.00--0.6614-----2.31-2.310.005.430.00----0.00-32.98---34.55--------------0.00-------6.80------
Mallinckrodt PLC2.02bn-867.10m142.58m2.80k--0.0771--0.0705-44.95-44.8941.31140.390.26242.075.00722,214.30-11.25-8.61-13.71-10.2126.1845.66-42.88-34.461.41-0.57020.6247---19.66--25.39------
RVL Pharmaceuticals PLC42.77m-53.05m142.78m156.00--2.08--3.34-0.6251-0.62570.50200.69130.322911.0415.39274,192.30-40.05-18.78-55.99-21.8681.3551.85-124.02-61.823.27-90.100.4493---90.16-39.64-4.10---35.47--
Matinas BioPharma Holdings Inc2.13m-24.06m143.13m31.00--3.71--67.36-0.111-0.1110.00980.17810.0371----68,548.39-42.02-51.16-45.60-55.50-----1,132.32-16,821.71----0.0002---78.95---1.89------
LAVA Therapeutics NV17.46m-26.53m144.85m55.00--1.53--8.30-1.54-1.540.71443.590.1161----317,487.40-17.64---18.77-------151.91------0.0476--42.86---192.45------
Artemis Therapeutics Inc195.00k-890.00k145.64m13.00------746.89-0.0284-0.02840.0065-0.00590.9899-------455.33-182.34----87.18---460.00--0.2201-----------37.86------
Singular Genomics Systems Inc0.00-89.54m145.65m269.00--0.5253-----1.26-1.260.003.880.00----0.00-25.00---25.72----------19.00--0.0349-------253.45------
Data as of Nov 30 2022. Currency figures normalised to Relmada Therapeutics Inc's reporting currency: US Dollar USD

Institutional shareholders

62.48%Per cent of shares held by top holders
HolderShares% Held
RTW Investments LPas of 30 Sep 20222.64m8.80%
Deep Track Capital LPas of 13 Oct 20222.48m8.25%
Perceptive Advisors LLCas of 30 Sep 20222.38m7.93%
BVF Partners LPas of 30 Sep 20222.08m6.91%
Point72 Asset Management LPas of 13 Oct 20222.03m6.76%
RA Capital Management LPas of 30 Sep 20222.00m6.65%
BlackRock Fund Advisorsas of 30 Sep 20221.85m6.16%
The Vanguard Group, Inc.as of 30 Sep 20221.39m4.61%
Citadel Advisors LLCas of 07 Oct 20221.33m4.44%
SSgA Funds Management, Inc.as of 30 Sep 2022590.13k1.96%
More ▼
Data from 30 Sep 2022 - 30 Sep 2022Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.